Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: HGF

Gene summary for HGF

Gene summary.

Gene information	Species	Human
	Gene symbol	HGF
	Gene ID	3082
	Gene name	hepatocyte growth factor
	Gene Alias	DFNB39
	Cytomap	7q21.11
	Gene Type	protein-coding
	GO ID	GO:0000165
	UniProtAcc	P14210

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
3082	HGF	ATC12	Human	Thyroid	ATC	1.06e-50	1.26e+00	0.34
3082	HGF	ATC13	Human	Thyroid	ATC	2.48e-11	2.29e-01	0.34
3082	HGF	ATC4	Human	Thyroid	ATC	5.56e-59	1.47e+00	0.34
3082	HGF	ATC5	Human	Thyroid	ATC	2.61e-10	2.60e-01	0.34

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:001082319	Thyroid	ATC	negative regulation of mitochondrion organization	26/6293	49/18723	3.87e-03	1.68e-02	26
GO:00104211	Thyroid	ATC	hydrogen peroxide-mediated programmed cell death	10/6293	14/18723	4.31e-03	1.80e-02	10
GO:190320125	Thyroid	ATC	regulation of oxidative stress-induced cell death	36/6293	74/18723	5.19e-03	2.12e-02	36
GO:006068813	Thyroid	ATC	regulation of morphogenesis of a branching structure	26/6293	50/18723	5.51e-03	2.24e-02	26
GO:00074312	Thyroid	ATC	salivary gland development	19/6293	34/18723	6.21e-03	2.48e-02	19
GO:00074352	Thyroid	ATC	salivary gland morphogenesis	18/6293	32/18723	7.00e-03	2.78e-02	18
GO:0060445	Thyroid	ATC	branching involved in salivary gland morphogenesis	13/6293	21/18723	7.34e-03	2.87e-02	13
GO:00507305	Thyroid	ATC	regulation of peptidyl-tyrosine phosphorylation	108/6293	264/18723	7.50e-03	2.93e-02	108
GO:00331371	Thyroid	ATC	negative regulation of peptidyl-serine phosphorylation	17/6293	30/18723	7.88e-03	3.06e-02	17
GO:00974681	Thyroid	ATC	programmed cell death in response to reactive oxygen species	10/6293	15/18723	9.05e-03	3.39e-02	10
GO:190040725	Thyroid	ATC	regulation of cellular response to oxidative stress	41/6293	89/18723	9.71e-03	3.56e-02	41
GO:00352722	Thyroid	ATC	exocrine system development	23/6293	45/18723	1.14e-02	4.06e-02	23
GO:0036474	Thyroid	ATC	cell death in response to hydrogen peroxide	17/6293	31/18723	1.21e-02	4.27e-02	17
GO:1902882110	Thyroid	ATC	regulation of response to oxidative stress	44/6293	98/18723	1.30e-02	4.55e-02	44

Page: 1 2 3 4 5

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand	Receptor	LRpair	Pathway	Tissue	Disease Stage
HGF	MET	HGF_MET	HGF	Breast	Healthy
HGF	MET	HGF_MET	HGF	Cervix	Precancer
HGF	MET	HGF_MET	HGF	Endometrium	EEC
HGF	MET	HGF_MET	HGF	Liver	HCC
HGF	MET	HGF_MET	HGF	Liver	Healthy
HGF	MET	HGF_MET	HGF	Liver	Precancer
HGF	MET	HGF_MET	HGF	Lung	IAC
HGF	MET	HGF_MET	HGF	Prostate	BPH
HGF	MET	HGF_MET	HGF	Prostate	Healthy
HGF	MET	HGF_MET	HGF	THCA	Cancer

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

HGF

SNV

Missense_Mutation

novel

c.1535G>T

p.Arg512Ile

p.R512I

P14210

protein_coding

deleterious(0.02)

benign(0.054)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

HGF

SNV

Missense_Mutation

c.1748N>C

p.Lys583Thr

p.K583T

P14210

protein_coding

deleterious(0)

probably_damaging(0.998)

TCGA-AN-A0AK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

HGF

SNV

Missense_Mutation

c.377N>C

p.Arg126Thr

p.R126T

P14210

protein_coding

deleterious(0)

probably_damaging(0.997)

TCGA-AR-A0TZ-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unspecific

Doxorubicin

HGF

SNV

Missense_Mutation

c.248C>G

p.Thr83Ser

p.T83S

P14210

protein_coding

tolerated(0.35)

benign(0.006)

TCGA-BH-A0BF-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

HGF

SNV

Missense_Mutation

c.1913N>A

p.Gly638Glu

p.G638E

P14210

protein_coding

deleterious(0.03)

probably_damaging(0.979)

TCGA-C8-A26W-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

HGF

SNV

Missense_Mutation

rs778704152

c.1675N>A

p.Glu559Lys

p.E559K

P14210

protein_coding

tolerated(0.44)

probably_damaging(0.992)

TCGA-GM-A2D9-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

HGF

SNV

Missense_Mutation

rs777593933

c.589C>T

p.Arg197Cys

p.R197C

P14210

protein_coding

deleterious(0)

probably_damaging(0.998)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

HGF

SNV

Missense_Mutation

c.686N>C

p.Gly229Ala

p.G229A

P14210

protein_coding

deleterious(0)

possibly_damaging(0.672)

TCGA-C5-A1BQ-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Chemotherapy

cisplatin

HGF

SNV

Missense_Mutation

c.343N>C

p.Glu115Gln

p.E115Q

P14210

protein_coding

tolerated(0.28)

benign(0.352)

TCGA-C5-A1BQ-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Chemotherapy

cisplatin

HGF

SNV

Missense_Mutation

c.331G>A

p.Glu111Lys

p.E111K

P14210

protein_coding

tolerated(0.86)

benign(0)

TCGA-C5-A1MH-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
3082	HGF	PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME		STI571	IMATINIB MESYLATE	11439348
3082	HGF	PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME		THALIDOMIDE	THALIDOMIDE	15939924
3082	HGF	PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME		ASPIRIN	ASPIRIN	11981761
3082	HGF	PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME		VM-202
3082	HGF	PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME		Ficlatuzumab	FICLATUZUMAB
3082	HGF	PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME		PROTEOLYTIC ENZYMES		9502079
3082	HGF	PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME	antibody	RILOTUMUMAB	RILOTUMUMAB
3082	HGF	PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME		RESVERATROL	RESVERATROL	15672869
3082	HGF	PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME		TAK-701
3082	HGF	PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME		FICLATUZUMAB	FICLATUZUMAB

Page: 1 2 3